<DOC>
	<DOCNO>NCT02043002</DOCNO>
	<brief_summary>Erlotinib , anti-cancer agent target epidermal growth factor receptor ( EGFR ) , active treatment patient non-small cell lung cancer ( NSCLC ) . Effect treatment primary see patient harbor mutation EGFR . However , 10-15 % patient harbor mutation respond well . Identifying patient problem method lack . Studies show early 18F FDG-PET might predict response outcome patient , study need confirm finding .</brief_summary>
	<brief_title>Early Changes Positron Emissions Tomography ( PET/CT ) Scan Predictors Clinical Outcome NSCLC Treated With EGFR Tyrosin Kinase Inhibitors ( TKI )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Lung Cancer patient nonsmall cell histology stage IV disease candidate erlotinib treatment first/ second/ third line treatment pregnancy severe dyspnoea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>